Psychedelic Therapy

play_circle

Myths, the market and the possibilities

Have you heard of psychedelic therapy? If not, you will soon! Mind-expanding drugs such as psilocybin, LSD, MDMA and ketamine have been illegal for 50 years – both recreationally and in research. But it is all changing rapidly. Studies in recent years indicate that these substances have a radical potential to alleviate widespread mental disorders such as stress, anxiety, depression and PTSD. And with up to 300 million depressed people in the world, action is desperately needed. The researchers' promising results have led to unprecedented interest from the outside world, and the wave of investment and patent wars in the field clearly confirms that commercial interests also find the potential absolutely enormous. This presentation takes a closer look at 1) the need for psychedelic therapy, 2) the promising trials that confirm the potential and 3) the key companies driving the development.

Foredragsholder: Denis Rivin

Varighed: 45 - 90 minutter

Emner: Brain research, Challenges, Clima, Climate and Sustainability, Focus, Future, Future and Research, Future trends, Meditation, Mental training, Performance, Personal development, Psychology og Sustainability

Sprog: Dansk

Tilgængelighed:

Tilgængelig fysisk og online

The product is available in the regions: Capital Region, Zealand, Funen